HRTX Q2 2022 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+23.1% YoY

Gross Profit

$11M41.5% margin

Operating Income

-$49M-179.1% margin

Net Income

-$56M-204.0% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+17.8%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$244M

Total Liabilities

$266M

Stockholders' Equity

-$22M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$22M	+23.1%
Gross Profit	$11M	$8M	+44.6%
Operating Income	-$49M	-$60M	+18.1%
Net Income	-$56M	-$61M	+7.6%

Revenue Segments

C I N V A N T I

$23M82%

Z Y N R E L E F

$3M9%

S U S T O L

$2M9%